Member Info for stephen11

Good point - there is always an opportunity cost with stocks. Should the profit be moved elsewhere or will the money bag a few more times where it.

It’s a lithium play starting with a K, but I don’t want to cross ramp ☺️

I asked the question PubCrawl as I’ve regretted not selling shares at the right time before - nearer the top I mean.

To answer your question - 10p will be my topslice and I’m not share when to sell the rest - I have a share in mind for the profits though.

Not the topslice and free run price - your exit price??

See news flow for Dec 23 and Jan 24, summarised from the presentation with comments from James Cheek:

- Revenue in the UK and abroad for MTRNR-1 hearing product (Sussex Trust already life)

* Expecting to see orders from around Europe in Dec 23 (EU Market worth £46.75M annually) and more UK Trusts

- Promotion of MTRNR-1 through Health Innovation Networks

* Talks ongoing with Scotland and Wales

- Special Commissioning for MTRNR-1

* James states "Pretty much got absolute 100% clarity that it is happening" (UK market worth £8.5M annually)

- FDA registration for MTRNR-1

* James states that contracts with a US partner for FDA are being finalised and we should hear news this year or early next, on the back of extremely positive talks with the FDA (USA market worth £34M annually)

- NICE recommendation for MTRNR-1

* NICE full validation for the MTRNR-1 is being hindered by the EVO process itself and not the product. News due Jan 24 says James Cheek

- NICE review for CYP2C19

* News due Jan 2024 says James Cheek (UK market worth £8.5M annually)

- Testing in Manchester Trust for CYP2C19 and Europe

* Testing for the adverse reaction to Clipidogrel in stroke patients to roll out in Dec 23. Also being actively marketed around Europe as a research only product (EU Market worth £93.5M annually)

- Future funding activities to support FDA

* Support of US partner and specific fundraise for FDA in Q1

GLA.

Stephen11.

It saddens me to say it but this is a kick the can down the road RNS.

We can apply a grant in Oct 2024 to accelerate the EVO process for MTRNR-1….what happened to Cheek saying Specialist Commissioning will happen.

I’m normally an upbeat guy as and like to give people the benefit of the doubt but this is NOT good.

GLA.

Stephen11.

Filtered

Reconnect - I’ve just disconnected you.

Small correction - 1899km - to much wine last night 🤣.

Thanks for the link Castlepaul13,

Well worth a read.

Highlights - HE1 own the mining right to 12 concessions with a total area of 8990 KM 😊 - as perspective that’s three quarters the size of Northern Ireland - it’s huge 🤛

Onlyprofit - sincerely hope it all comes good for you mate. I bet there’s not a person on here who hasn’t been in a similar situation at one time or another. Hang in there.

Bighammer - Cheek came across extremely well at the last meeting and I hope he can turn things around. What we do know, historically, is that this share is a speedboat and not a trawler when it gets going. Heres to better days ahead 😀😀.

GLA.

Stephen11.

Agreed Bighammer,

We need to see if Cheeks actions match his words from the last investormeetcompany presentation - and soon!

GLA.

Stephen11.

Can anyone remember the good old days pre-internet when you got share prices on teletext or in the Financial Times?

Buys at 2.45 and +30% on HL

4.0

Jan 2024 @typo

**Stroke Test - CYP2CI9**

- GDR has a competitor in the market, however this is not a proper point of care test, has a longer test time, and has limited capabilities compared with the CYP2C19 test

- The Total Addressable Market is around £220M: UK £8.5M / EU £93.5M / US £67.58M / ROI 51M

- The Manchester Health Trust will be starting to use this product routinely in late Dec 23 or early Jan 24 (surprised this has not been announced yet)

- GDR are actively speaking to other health trusts around the UK and have garnered a considerable amount of interest

- The CYP2CI9 test is being actively marketed around Europe as a research only product - to create interest around the various countries and to create early commercial traction

- A US peer reviewed study has shown that hospitalisation from an adverse reaction to Clipidogrel costs on average $8 to $20 thousand dollars per person - the CYP2CI9 test would eradicate this cost

- News on NICE was due January 2014, but as others have mentioned this date hasn't materialised.

GLA.

Stephen11.

Wait till we start to get drill results on the gold, more lithium drill results, and updates on the plant - 2024 should be a blinder.

In context - Kodal own gold resources that are approximately 3 times the size of the Isle of man!

Detailed breakdown below:

Names and numbers for the Gold concessions in Cote d'Ivoire and Corvette

Corvette:

PR-399 212 Km² (NIELLE)

PR400 396.761 Km² (M’BIHIAKRO)

PR-398 229.02 Km² (TIEBISSOU)

International Goldfields Cote d’Ivoire

PR0834 394.7647Km² (BOUNDIALI)

PR-427 200.4052Km² (KORHOGO)

PR-426 220.7688 Km² (DABAKALA)

Obviously, i would presume the gold will not be evenly distributed amongst this land and the ongoing testing will be needed to identify the best ground - but its vast!

GLA.

Stephen11.

Stroke @typo

I’ve some stoke info - I’ll post it later tonight or tomorrow DSFLAT - I’m rushing to get to a 3pm kickoff.

Lot’s of news to come here near term.

Stephen11.

In answer to your question Popeye - this is the lowest this share has been in the last 5 years. Even lower than when the entire market fell off a cliff in March 2020 in the midst of Covid.

I bought a shed load here at 6/7p and thought that was the bottom, but you live and learn.

News due on multiple fronts, so hopefully “the only way is up” to quote DReam🤣.

GLA.

Stephen11.

It would be lovely if we could get an RNS like Hemo with the magic words FDA in the title - and best of luck to them.

Ooh well - are day will come 🤛